Latest News for GIFLF
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian…
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency…
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GIFLF.
Senate Trading
No Senate trades found for GIFLF.
U.S. House Trading
No House trades found for GIFLF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.